Advanced search
Publication Cover
Postgraduate Medicine Volume 126, 2014 - Issue 6
Submit an article Journal homepage
244
Views
9
CrossRef citations to date
0
Altmetric
Clinical Focus: Metabolic Syndrome, Diabetes, and Immunizations

The Biosimilar Insulin Landscape: Current Developments

Fernando J. Lavalle-González Universidad Autonoma de Nuevo Leon, Monterrey, MexicoCorrespondence[email protected]
, MD &
Hootan Khatami Sanofi, Bridgewater, NJ
, MD
Pages 81-92 | Published online: 13 Mar 2015

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jingbo Hu, Min Wang & Yufen Zhao. (2018) SAR342434 - an insulin biosimilar for the treatment of type II diabetes. Expert Opinion on Biological Therapy 18:11, pages 1107-1112.
Read now

Articles from other publishers (8)

Shilpa Mohanty, Babbal & Yogender Pal Khasa. 2023. Fungi and Fungal Products in Human Welfare and Biotechnology. Fungi and Fungal Products in Human Welfare and Biotechnology 513 569 .
Thomas Danne, Lutz Heinemann & Jan Bolinder. (2021) New Insulins, Biosimilars, and Insulin Therapy. Diabetes Technology & Therapeutics 23:S2, pages S-46-S-68.
Crossref
Steven R. Feldman, Jerry Bagel & Shahla Namak. (2018) Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know. The American Journal of the Medical Sciences 355:5, pages 411-417.
Crossref
Carolyn Tieu, Eleanor J. Lucas, Mindi DePaola, Lori Rosman & G. Caleb Alexander. (2018) Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLOS ONE 13:4, pages e0195012.
Crossref
Xia Hu, Lei Zhang, Yanhu Dong, Chao Dong, Jikang Jiang & Weiguo Gao. (2018) Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review. F1000Research 7, pages 477.
Crossref
Lutz HeinemannIngo FritzHootan KhatamiSteven V. Edelman. (2017) Administration of Biosimilar Insulin Analogs: Role of Devices. Diabetes Technology & Therapeutics 19:2, pages 79-84.
Crossref
H. A. Dowlat, M. K. Kuhlmann, H. Khatami & F. J. Ampudia-Blasco. (2016) Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes, Obesity and Metabolism 18:8, pages 737-746.
Crossref
Thomas DanneLutz HeinemannJan Bolinder. (2016) New Insulins, Biosimilars, and Insulin Therapy. Diabetes Technology & Therapeutics 18:S1, pages S-43-S-55.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.